Previous 10 | Next 10 |
10x Genomics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference PR Newswire PLEASANTON, Calif. , Sept. 2, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human he...
10x Genomics, Inc. ( NASDAQ: TXG ) dropped ~6% in the pre-market trading Thursday after Gladman Sachs downgraded the life sciences company to Sell from Neutral, citing a significantly slower trajectory for its future sales growth. The price target set to $35 per share impl...
Recent volatility mirror renewed meme-trade bonanza, likely to subdue in coming days, instead of a reflection of a change in the company's market position. Several factors distorted the YoY revenue comparison this quarter, contributing to the inflated top-line growth, including the Bi...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Fifth Avenue Growth Fund (the “Fund”) lost 30.6% (Institutional Shares) during the second quarter. ...
Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...
10x Genomics, Inc. (TXG) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer & Co-founder Jim Wilbur - Chief Commercial Officer J...
10x Genomics press release ( NASDAQ: TXG ): Q2 GAAP EPS of -$0.57. Revenue of $114.61M (-1.1% Y/Y). Shares -2% . Outlook: 10x Genomics is updating its outlook for the full year 2022. The company now expects revenue to be in the range of $500 million to $520 mil...
10x Genomics Reports Second Quarter 2022 Financial Results PR Newswire PLEASANTON, Calif. , Aug. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2022. Recent Highli...
Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...
This year, two major catalysts for SoftBank are the potential sale of the Fortress Investments subsidiary and the Arm IPO. This complicated company has faced underperformance over the past few years, especially after the 2020 speculation boom. However, if valuation reaches a certa...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...